| Literature DB >> 34068498 |
Johannes Laimer1, Alexander Höller2, Ute Pichler2, Raphael Engel1, Sabrina B Neururer3, Alexander Egger4, Andrea Griesmacher4, Emanuel Bruckmoser5.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe side effect of mostly antiresorptive drugs. The aim of this prospective clinical study was to evaluate the nutritional status in MRONJ patients scheduled for surgical treatment (intraoral soft tissue closure). The following parameters were evaluated: body weight, body height, BMI, nutritional risk index (NRI), bioelectric impedance analysis (BIA), vitamins A, B12, D3, E, K1, folic acid, iron, total protein, transferrin, ferritin, prealbumin, albumin, and zinc. All subjects were admitted to hospital four to five days before surgery and sip-fed with Nutritia Fortimel Compact Protein in addition to regular oral food intake. During surgery, a nasogastric tube was inserted and only removed on hospital discharge five days postoperatively. A total of 58 patients could be included. Half of the MRONJ patients were identified to be at risk for malnutrition. Deficiencies regarding protein levels were revealed, whereas hardly any relevant deficits of micronutrients were noted. The intraoral wound healing four weeks post-surgery was highly satisfactory with a low dehiscence rate of intraoral mucosal sites. Of all parameters analyzed, the dehiscence rate at the last follow-up four weeks post-surgery was significantly influenced by vitamin K, transferrin, and ferritin levels (p = 0.030, p = 0.004, and p = 0.023, respectively). In conclusion, perioperative dietary counselling and appropriate nutritional therapy are important supportive measures in MRONJ patients scheduled for intraoral soft tissue closure.Entities:
Keywords: MRONJ; macronutrients; malnutrition; medication-related osteonecrosis of the jaw; micronutrients; nutritional status; nutritional therapy; wound healing
Year: 2021 PMID: 34068498 PMCID: PMC8151518 DOI: 10.3390/nu13051585
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Basic characteristics of the study population (n = 58).
| Variables | Readings |
|---|---|
| Age (years) | 70.5 (42; 86) |
| Female | 31 (53%) |
| Male | 27 (47%) |
| Weight (cm) ± SD | 71.5 ± 15.4 |
| Height (kg) ± SD | 168.8 ± 8.9 |
| BMI ± SD | 25.1 ± 4.8 |
| Smoking (yes) | 8 (14%) |
| Alcohol (yes) | 20 (35%) |
BMI: body mass index, SD: standard deviation.
Underlying diseases/indications for antiresorptive therapy (n = 58).
| Diseases | Absolute Numbers | Percentage |
|---|---|---|
| Breast cancer | 18 | 31% |
| Prostate cancer | 13 | 22% |
| Lung cancer | 5 | 9% |
| Multiple myeloma | 11 | 19% |
| Colon carcinoma | 1 | 2% |
| Osteoporosis | 10 | 17% |
MRONJ stages in absolute numbers and percent.
| MRONJ Stage | Absolute Numbers | Percentage |
|---|---|---|
| MRONJ stage 1 | 13 | 22% |
| MRONJ stage 2 | 42 | 72% |
| MRONJ stage 3 | 3 | 5% |
MRONJ: medication-related osteonecrosis of the jaw.
Type of antiresorptive medication (n = 58).
| Drugs | Absolute Numbers | Percentage |
|---|---|---|
| Denosumab | 27 | 47% |
| Bisphosphonate | 10 | 17% |
| Denosumab and Bisphosphonate | 21 | 36% |
Intraoral mucosal status at different points in time (absolute numbers and percentages).
| Time Points | Closed Wound | Dehiscence | ||
|---|---|---|---|---|
| t2 | 58 | 100% | 0 | 0% |
| t3 | 50 | 86% | 8 | 14% |
| t4 | 47 | 83% | 10 | 17% |
t2: hospital discharge, t3: removal of sutures, t4: one month after surgery. At t4, one patient’s status was missing.
Absolute numbers and percentages of NRS scores (n = 58).
| NRS Score | Absolute Numbers | Percentage |
|---|---|---|
| 0 | 4 | 7% |
| 1 | 7 | 12% |
| 2 | 14 | 24% |
| 3 | 18 | 31 |
| 4 | 10 | 17% |
| 5 | 4 | 7% |
| 6 | 1 | 2% |
NRS: nutritional risk screening.
Anthropometric measurements at different points in time (t1, t2, t4). p-values < 0.017 are statistically significant.
| t1 MRONJ | t2 MRONJ | t4 MRONJ | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | ||||
|
| 4.6 | 1.1 | 4.9 | 3.6 |
| 4.5 | 1.0 | 0.847 |
|
|
| 31.6 | 8.5 | 31.3 | 8.7 | 0.823 | 31.1 | 8.0 | 0.788 | 0.155 |
|
| 23.2 | 9.4 | 22.5 | 9.3 |
| 22.3 | 8.5 | 0.380 | 0.019 |
|
| 21.3 | 6.5 | 20.1 | 5.6 |
| 21.0 | 6.3 |
| 0.139 |
|
| 43.6 | 6.5 | 42.5 | 6.3 |
| 43.4 | 6.5 | 0.073 | 0.264 |
|
| 19.0 | 4.4 | 18.3 | 3.6 | 0.171 | 18.5 | 3.5 | 0.075 | 0.389 |
|
| 53.0 | 6.3 | 54.1 | 6.1 |
| 53.1 | 6.2 | 0.040 | 0.330 |
|
| 48.2 | 9.6 | 47.0 | 8.7 |
| 47.6 | 9.3 |
| 0.032 |
|
| 25.1 | 4.8 | 24.4 | 4.6 |
| 24.6 | 4.5 |
|
|
|
| 104.7 | 11.6 | 99.6 | 11.6 |
| 106.2 | 10.2 |
| 0.384 |
MRONJ: medication-related osteonecrosis of the jaw; SD: standard deviation; BIA: bioelectrical impedance analysis; BCM: body cell mass; ECW: extracellular water; ECWI: extracellular water in liters; FFM: fat free mass (in kilograms); BMI: body mass index; NRI: nutritional risk index; significant p-values in bold.
Blood serum values of vitamins, proteins, and micronutrients at different points in time (t1, t2, t4). p-values < 0.017 are statistically significant.
| t1 MRONJ | t2 MRONJ | t4 MRONJ | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | ||||
|
| 329.7 | 167.6 | 477.5 | 272.7 |
| 391.5 | 261.2 |
|
|
|
| 8.3 | 5.3 | 10.0 | 4.6 |
| 8.3 | 3.9 |
| 0.096 |
|
| 813.3 | 496.7 | 1021.7 | 728.5 | 0.074 | 1227.5 | 879.8 | 0.105 |
|
|
| 0.5 | 0.2 | 0.5 | 0.2 | 0.127 | 0.6 | 0.2 |
| 0.018 |
|
| 15.6 | 4.0 | 15.6 | 3.2 | 0.951 | 17.1 | 4.6 | 0.037 | 0.068 |
|
| 70.4 | 40.1 | 71.3 | 36.7 | 0.626 | 74.1 | 33.7 | 0.291 | 0.095 |
|
| 11.3 | 1.6 | 15.4 | 27.7 | 0.281 | 11.3 | 1.6 | 0.564 | 0.583 |
|
| 14.4 | 7.0 | 12.0 | 4.8 |
| 14.5 | 6.4 |
| 0.825 |
|
| 230.2 | 45.3 | 216.9 | 44.9 |
| 244.3 | 46.3 |
|
|
|
| 298.2 | 438.0 | 301.9 | 482.1 |
| 209.0 | 244.9 |
| 0.017 |
|
| 22.8 | 5.9 | 21.0 | 5.3 |
| 25.6 | 6.7 |
|
|
|
| 3742.1 | 465.4 | 3492.5 | 486.5 |
| 3865.4 | 407.4 |
|
|
|
| 7.1 | 0.7 | 6.8 | 0.7 |
| 7.1 | 0.6 |
| 0.849 |
MRONJ: medication-related osteonecrosis of the jaw; SD: standard deviation; significant p-values in bold.